Honeywell Real-Time Health Monitoring System Improves Caregiver Efficiency While Reducing Hospital Readmissions and Delivering Better Patient Care

Advanced sensor technology and data analytics help improve patient monitoring of vital signs and care delivery in remote environments. Combination of hardware and software automates time-consuming and critical tasks for medical personnel, reducing workloads and potential errors

Honeywell (Nasdaq: HON) announced today it has developed a real-time health monitoring system, which captures and records patients’ vital signs both within the hospital setting and remotely. Honeywell’s solution uses advanced sensing technology to monitor vital signs via a skin patch, which connects the data instantaneously to healthcare providers on mobile devices and an online dashboard.

The Association of American Medical Colleges projects there will be a physician shortage of between 37,800 and 124,000 physicians by 2034. Hospital systems and healthcare providers are already preparing for the clinician shortfall by implementing technologies and tools to improve efficiency, while still maintaining high levels of care. Honeywell’s real-time health monitoring system provides doctors and nurses a solution to remotely monitor patients in the hospital or at home. The system, designed to be continuously connected to patients, alerts clinicians to changes in patients’ vital signs, and markedly reduces the time required to collect, analyze and apply patient data as actionable insights.

By automating essential processes, the remote monitoring system can help reduce clinician workloads and potentially save hours of error-prone administrative tasks. Across the healthcare industry, the growing trend of telemedicine and implementing remote patient monitoring is helping enhance the overall patient experience.

Robert Robinson, healthcare vice president and general manager, Honeywell Sensing & Safety Technologies.

“Safety and attentiveness are basic expectations for patients being treated in hospitals, and continuous patient monitoring is a necessity for doctors and nurses to provide best-in-class medical care,” said “Our solution provides intelligent alerts in the system, helping healthcare providers monitor patients concurrently and improve response time when emergency intervention is needed. At Honeywell, we are committed to a future in which healthcare providers have digital tools to make their jobs more efficient and accurate, and where every patient can receive high-quality care – where and when they need it.”

This technology unlocks the ability to provide care for patients in the home, at ambulatory care centers, or elsewhere outside of hospital walls. By bringing vital sign monitoring closer to where patients live, patients can receive care in their own environments, hospital readmissions can be reduced and beds can be freed up for those requiring in-person attention. Honeywell’s system will also help improve patient quality of life and satisfaction, an often overlooked benefit of remote monitoring. The ability to have vitals monitored in real time, regardless of where patients are, provides greater freedom and flexibility without needing to make regular trips to the hospital or being tethered to a hospital bed.

The healthcare industry is continuously evolving to maintain environments where clinicians can deliver high-quality care to patients. The real-time health monitoring system is part of Honeywell’s robust portfolio of healthcare technologies that drive better patient outcomes.

Honeywell Safety and Productivity Solutions (SPS) provides products, software and connected solutions that improve productivity, workplace safety and asset performance for our customers across the globe. We deliver on this promise through industry-leading mobile devices, software, cloud technology and automation solutions, the broadest range of personal protective equipment and gas detection technology, and custom-engineered sensors, switches and controls. Visit here.

SourceHoneywell

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”